Sartorius Stedim Biotech SA
F:56S0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sartorius Stedim Biotech SA
F:56S0
|
FR |
|
Hydrocarbon Dynamics Ltd
ASX:HCD
|
AU |
|
S
|
Shin-Etsu Chemical Co Ltd
F:SEH
|
JP |
|
N
|
Nufarm Ltd
F:NUF
|
AU |
|
S
|
SK Hynix Inc
XMUN:HY9H
|
KR |
|
C
|
CBRE Group Inc
DUS:RF6
|
US |
|
Silver Mountain Resources Inc
TSX:AGMR
|
CA |
|
I
|
Illinois Tool Works Inc
DUS:ILT
|
US |
|
Next Biometrics Group ASA
OSE:NEXT
|
NO |
|
PTC Therapeutics Inc
F:BH3
|
US |
|
Alaska Silver Corp
F:MK7
|
US |
|
S
|
Siltronic AG
LSE:0R8P
|
DE |
Wall St Price Targets
56S0 Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for 56S0 is 21.87 EUR with a low forecast of 19.49 EUR and a high forecast of 25.28 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 56S0's stock price target?
Price Target
21.87
EUR
According to Wall Street analysts, the average 1-year price target for 56S0 is 21.87 EUR with a low forecast of 19.49 EUR and a high forecast of 25.28 EUR.
What is the Revenue forecast for Sartorius Stedim Biotech SA?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 8 years is 12%.
What is the Operating Income forecast for Sartorius Stedim Biotech SA?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 8 years is 17%.
What is the Net Income forecast for Sartorius Stedim Biotech SA?
Projected CAGR
23%
Over the last 13 years, the compound annual growth rate for Net Income has been 13%. The projected CAGR for the next 8 years is 23%.
